Pharma & Bio
Lifestyle
A Hidden Gem Emerges Amid a Market Focused on Biotech Earnings... Three Reasons to Watch Remedy
The investment paradigm in the biotech and medical device market is rapidly shifting from a focus on mere “future value” to a focus on “companies backed by concrete performance and proven numbers.” Am…
Lifestyle
A Fortress-Like Partnership That Broke Through 11 Big Tech Giants: Leading 'K-Bio' into North America [In-Depth Look at Wise birds Inc. ①]
Wise birds Inc.(273060)is drawing attention as it begins in earnest to support domestic pharmaceutical and biotech companies in entering the U.S. direct-to-consumer (DTC) market. The company’s strateg…
Lifestyle
"First Company Under the Advanced Biotechnology Act," ViGenCell Inc., Set to Administer Treatment to First Patient Soon… Aims for Conditional Approval Next Year and a License-Out Deal in China
"Once treatment of the first patient begins, the next steps will be conditional approval, followed by technology export."With ViGenCell Inc.(308080)’s VT-EBV-N—the first treatment plan in Korea to rec…
Lifestyle
"All That's Left Is Commercialization"... Mezion Pharma Co., Ltd.'s Fontan Treatment Draws Interest from Global Big Pharma
Mezzion Pharma Co., Ltd.(140410)has further enhanced the scientific credibility of its Fontan patient treatment, “Udenafil,” by presenting research results demonstrating its efficacy in improving live…
Business·Industry
HLB INC.’s New Liver Cancer Drug Receives Third CRL… Delays in Approval Raise Concerns About Commercial Viability
HLB INC.(028300)’s new liver cancer drug, the combination therapy of “Riboceranib and Camrelizumab,” has received its third Complete Response Letter (CRL) from the U.S. Food and Drug Administration (F…
Technology
Jeong Do-hyun, CEO of Raphas Co., Ltd.: “Allergy Drug in Efficacy Validation Phase… Technology Transfer Possible Even with Phase 1 Results”
“The most challenging stage in the development of microneedle-based pharmaceuticals is demonstrating clinical efficacy. Since Raphas Co., Ltd. has largely secured its production technology infrastruct…
Lifestyle
Dop Signs Consecutive LOIs with Global Organization Bank... 'Global Full-Chain Business Model' Officially Launched
DOP, a company specializing in decellularized human tissue, is accelerating its expansion into the global market by signing a series of Letters of Intent (LOIs) with global tissue banks, leveraging it…
Lifestyle
'World's Only' Ring-Type Blood Pressure Monitor... Will SkyLabs Become the Next SEERS?
SkyLabs, which is pursuing a KOSDAQ listing, is drawing attention for its steep sales growth even before going public. Although numerous domestic and international companies have attempted to develop …
Technology
Biotech Stocks Rally Despite Setbacks at Peptron and HLB [K-Bio Pulse]
Peptron and HLB Group companies plunged to their daily lower limits on July 10 amid separate setbacks. Despite the sharp sell-offs, buying momentum spread across the broader KOSDAQ market, lifting man…
Business·Industry
Despite the Peptron, Inc. and HLB INC. Shock, the Biotech Sector Remains Bullish… Warm Sentiment Spreads Across KOSDAQ [Biotech Spotlight]
On the 10th, in the biotech sector, Peptron, Inc.(087010)and #HLB INC. all hit their daily price limits due to individual negative factors. Nevertheless, buying momentum spread across the KOSDAQ marke…